Translating stem cell discoveries

Stem Cells Handbook: Second Edition

Volumn , Issue , 2013, Pages 377-389

  Trounson, Alan ^a  

^a California Institute for Regenerative Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905757158     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-7696-2_26     Document Type: Chapter

References (64)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-7.
2. Reubinoff BE, Pera MF, Fong C-Y, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000;18(4):399-404.
3. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-72.
4. Trounson A. CIRM the way ahead. Regen Med. 2011;6(3):285-90.
5. Gimble JM, Bunnell BA, Guilak F. Human adipose-derived cells: an update on the transition to clinical translation. Regen Med. 2012;7(2):225-35.
6. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, Conway SJ, Fu JD, Srivastava D. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature. 2012;485(7400):593-8.
7. Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, Acharya A, Smith CL, Tallquist MD, Neilson EG, Hill JA, Bassel-Duby R, Olson EN. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature. 2012;485(7400):599-604.
8. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K, Zhang Z, Rosenberg P, Mirotsou M, Dzau VJ. MicroRNA- mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res. 2012;110(11):1465-73.
9. Migliaccio AR, Whitsett C, Papayannopoulou T, Sadelain M. The potential of stem cells as an in vitro source of red blood cells for transfusion. Cell Stem Cell. 2012;10(2):115-9.
10. Takayama N, Eto K. In vitro generation of megakaryocytes and platelets from human embryonic stem cells and induced pluripotent stem cells. Methods Mol Biol. 2012;788:205-17.
11. Caldas HC, Hayashi AP, Abbud-Filho M. Repairing the chronic damaged kidney: the role of regenerative medicine. Transplant Proc. 2011;43(10):3573-6.
12. Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology. 2012;55(1):298-306.
13. Kotton DN. Next generation regeneration: the hope and hype of lung stem cell research. Am J Respir Crit Care Med. 2012;185(12):1255-60.
14. Elliott MJ, De Coppi P, Speggiorin S, Roebuck D, Butler CR, Samuel E, Crowley C, McLaren C, Fierens A, Vondrys D, Cochrane L, Jephson C, Janes S, Beaumont NJ, Cogan T, Bader A, Seifalian AM, Hsuan JJ, Lowdell MW, Birchall MA. Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study. Lancet. 2012;380(9846):994-1000.
15. Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, Gavrilov K, Yi T, Zhuang ZW, Breuer C, Herzog E, Niklason LE. Tissue-engineered lungs for in vivo implantation. Science. 2010;329(5991):538-41.
16. Nakano T, Ando S, Takata N, Kawada M, Muguruma K, Sekiguchi K, Saito K, Yonemura S, Eiraku M, Sasai Y. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell. 2012;10(6):771-85.
17. Trounson A, Baum E, Gibbons D, Tekamp-Olson P. Developing a model for successful translation of stem cell therapies. Cell Stem Cell. 2010;6(6):513-6.
18. Wonnacott K, Lavoie D, Fiorentino R, McIntyre M, Huang Y, Hirschfeld S. Investigational new drugs submitted to the FDA that are placed on clinical hold: the experience of the office of cellular, tissue and gene therapy. Cytotherapy. 2008;10(3):312-31.
19. U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for industry: formal meetings between the FDA and sponsors or applicants. 2009. http://www.fda.gov/downloads/Drugs/Guidances/ucm153222.pdf.
20. Maciulaitis R, D'Apote L, Buchanan A, Pioppo L, Schneider CK. Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must Be proactive. Mol Ther. 2012;20(3):479-82.
21. Frey-Vasconcells J, Whittlesey KJ, Baum E, Feigal EG. Translation of stem cell research: points to consider in designing animal studies. Stem Cells Transl Med. 2012;1:353-8.
22. Kagami H, Agata H, Tojo A. Bone marrow stromal cells (bone marrow-derived multipotent mesenchymal stromal cells) for bone tissue engineering: basic science to clinical translation. Int J Biochem Cell Biol. 2011;43(3):286-9.
23. Ciapetti G, Granchi D, Baldini N. The combined use of mesenchymal stromal cells and scaffolds for bone repair. Curr Pharm Des. 2012;18(13):1796-820.
24. O'Keefe RJ, Mao J. Bone tissue engineering and regeneration: from discovery to the clinic-an overview. Tissue Eng Part B Rev. 2011;17(6):389-92.
25. Miller RH, Bai L. Translating cell therapies to the clinic. Neurosci Lett. 2012;519(2):87-92.
26. Dunnett SB, Rosser AE. Clinical translation of cell transplantation in the brain. Curr Opin Organ Transplant. 2011;16(6):632-9.
27. Lindvall O, Barker RA, Brüstle O, Isacson O, Svendsen CN. Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell. 2012;10(2):151-5.
28. Aboody K, Capela A, Niazi N, Stern JH, Temple S. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron. 2011;70(4):597-613.
29. Fornai F, Meininger V, Silani V. Future therapeutical strategies dictated by pre-clinical evidence in ALS. Arch Ital Biol. 2011;149:169-74.
30. Lindvall O, Björklund A. Cell therapeutics in Parkinson's disease. Neurotherapeutics. 2011;8(4):539-48.
31. Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med. 2012;10:1.
32. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Björklund A, Lindvall O, Piccini P. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med. 2012;4(128):128ra41.
33. Politis M. Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? BMC Med. 2010;8:80.
34. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med. 2010;2:38-46.
35. Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bjorklund A, Lindvall O, Piccini P. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov Disord. 2011;11:1997-2003.
36. Braak H, Del Tredici K. Assessing fetal nerve cell grafts in Parkinson's disease. Nat Med. 2008;14:483-5.
37. Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011;480(7378):547-51.
38. Hook L, Vives J, Fulton N, Leveridge M, Lingard S, Bootman MD, Falk A, Pollard SM, Allsopp TE, Dalma-Weiszhausz D, Tsukamoto A, Uchida N, Gorba T. Non-immortalized human neural stem (NS) cells as a scalable platform for cellular assays. Neurochem Int. 2011;59(3):432-44.
39. Trounson A, Thaker R, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011;9(1):52.
40. Hwang DH, Jeong SR, Kim BG. Gene transfer mediated by stem cell grafts to treat CNS injury. Expert Opin Biol Ther. 2011;11(12):1599-610.
41. Trounson A. California institute for regenerative medicine: accelerating stem cell therapies in California and beyond. Stem Cells. 2012;30(3):357-9.
42. Trounson A, DeWitt ND, Feigal EG. A new model needed for the delivery of stem cell therapies in translation for regenerative medicine: the alpha stem cell clinic. Stem Cells Transl Med. 2012;1:9-14.
43. Noble M, Mayer-Pröschel M, Davies JE, Davies SJ, Pröschel C. Cell therapies for the central nervous system: how do we identify the best candidates? Curr Opin Neurol. 2011;24(6):570-6.
44. Burns TC, Steinberg GK. Stem cells and stroke: opportunities, challenges and strategies. Expert Opin Biol Ther. 2011;11(4):447-61.
45. Hernández J, Torres-Espín A, Navarro X. Adult stem cell transplants for spinal cord injury repair: current state in preclinical research. Curr Stem Cell Res Ther. 2011;6(3):273-87.
46. Johnson TV, Bull ND, Martin KR. Stem cell therapy for glaucoma: possibilities and practicalities. Expert Rev Ophthalmol. 2011;6(2):165-17.
47. Bull ND, Martin KR. Concise review: toward stem cell-based therapies for retinal neurodegenerative diseases. Stem Cells. 2011;29(8):1170-5.
48. Binello E, Germano IM. Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol. 2012;14(3):256-65.
49. Morgan RA, Johnson LA, Davis J, Zheng Z, Woolard K, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 2012;23(10):1043-53.
50. Sarig U, Machluf M. Engineering cell platforms for myocardial regeneration. Expert Opin Biol Ther. 2011;11(8):1055-77.
51. Malliaras K, Kreke M, Marban E. The stuttering progress of cell therapy for heart disease. Clin Pharmacol Ther. 2011;90(4):532-41.
52. Dixon JA, Spinale FG. Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol. 2011;73:47-68.
53. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD, Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110-9.
54. Choudry FA, Mathur A. Stem cell therapy in cardiology. Regen Med. 2011;6(6):17-23.
55. Loffredo FS, Steinhauser ML, Gannon J, Lee RT. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell. 2011;8:389-98.
56. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847-57.
57. Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, Matsushita N, Blusztajn A, Terrovitis J, Kusuoka H, Marbán L, Marbán E. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol. 2012;59(10):942-53.
58. Makkar RR, Smith RP, Cheng K, Malliaras K, Thomson LEJ, Berman D, Czer LSC, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895-904.
59. Henning TD, Gawande R, Khurana A, Tavri S, Mandrussow L, Golovko D, Horvai A, Sennino B, McDonald D, Meier R, Wendland M, Derugin N, Link TM, Daldrup-Link HE. Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells in cartilage defects: in vitro and in vivo investigations. Mol Imaging. 2012;11(3):197-209.
60. Fu Y, Azene N, Xu Y, Kraitchman DL. Tracking stem cells for cardiovascular applications in vivo: focus on imaging techniques. Imaging Med. 2011;3(4):473-86.
61. Boehm-Sturm P, Mengler L, Wecker S, Hoehn M, Kallur T. In vivo tracking of human neural stem cells with 19F magnetic resonance imaging. PLoS One. 2011;6(12):e29040.
62. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 2011;12(5):301-15.
63. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells. 2011;29(6):883-7.
64. Gimble JM, Bruce A, Bunnell BA, Ernest RS, Chiu ES, Guilak F. Concise review: adipose-derived stromal vascular fraction cells and stem cells: let's not get lost in translation. Stem Cells. 2011;29:749-54.